Skip to main content
. 2017 Nov 10;8(66):109861–109876. doi: 10.18632/oncotarget.22371

Figure 2. hMSC-EVs support primary breast tumor growth.

Figure 2

(A) tumor volume and (B) tumor weight, obtained from the NOD/SCID mice injected without or with hMSC-EV-primed MDA-MB-231 cells (left), organ-specific sublines to brain (middle), and lungs (right). Data are presented as the mean ± standard deviation. n = 6. (C) Representative images of hematoxylin and eosin staining of tumor sections showing more necrosis (black arrow), vessel formation (blue arrow), and pleomorphism (green arrow) in the hMSC-EV treated group. **P < 0.001; *P < 0.05.